MX2010004271A - Formulaciones de vacuna meningococica. - Google Patents

Formulaciones de vacuna meningococica.

Info

Publication number
MX2010004271A
MX2010004271A MX2010004271A MX2010004271A MX2010004271A MX 2010004271 A MX2010004271 A MX 2010004271A MX 2010004271 A MX2010004271 A MX 2010004271A MX 2010004271 A MX2010004271 A MX 2010004271A MX 2010004271 A MX2010004271 A MX 2010004271A
Authority
MX
Mexico
Prior art keywords
men
lyophilised
vaccine formulations
formulation
meningococcal vaccine
Prior art date
Application number
MX2010004271A
Other languages
English (en)
Spanish (es)
Inventor
Mario Contorni
Manmohan Singh
Jina Kazzaz
Derek O'hagan
Mildred Ugozzoli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010004271A publication Critical patent/MX2010004271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2010004271A 2007-10-19 2008-10-17 Formulaciones de vacuna meningococica. MX2010004271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99959007P 2007-10-19 2007-10-19
PCT/IB2008/003283 WO2009050586A1 (en) 2007-10-19 2008-10-17 Meningococcal vaccine formulations

Publications (1)

Publication Number Publication Date
MX2010004271A true MX2010004271A (es) 2010-05-03

Family

ID=40428348

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010004271A MX2010004271A (es) 2007-10-19 2008-10-17 Formulaciones de vacuna meningococica.
MX2012007222A MX340096B (es) 2007-10-19 2008-10-17 Formulaciones de vacuna meningococica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012007222A MX340096B (es) 2007-10-19 2008-10-17 Formulaciones de vacuna meningococica.

Country Status (20)

Country Link
US (2) US20100285069A1 (enExample)
EP (2) EP2462949A3 (enExample)
JP (3) JP5701058B2 (enExample)
CN (1) CN101951949B (enExample)
AT (1) ATE553774T1 (enExample)
AU (1) AU2008313424B2 (enExample)
BR (2) BRPI0818545A2 (enExample)
CA (2) CA2702871A1 (enExample)
CO (1) CO6270339A2 (enExample)
CY (1) CY1112908T1 (enExample)
DK (1) DK2200642T3 (enExample)
ES (1) ES2383231T3 (enExample)
HR (1) HRP20120433T1 (enExample)
MX (2) MX2010004271A (enExample)
NZ (1) NZ584683A (enExample)
PL (1) PL2200642T3 (enExample)
PT (1) PT2200642E (enExample)
RU (2) RU2498815C2 (enExample)
SI (1) SI2200642T1 (enExample)
WO (1) WO2009050586A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2008259423A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
CA2747340A1 (en) * 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EA026401B1 (ru) 2009-09-02 2017-04-28 Новартис Аг Иммуногенные композиции, содержащие модуляторы активности tlr
SI3246044T2 (sl) * 2010-08-23 2024-06-28 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
BR112013022397A2 (pt) 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante
IN2012MU00206A (enExample) * 2012-01-20 2013-08-09
RU2014140336A (ru) 2012-03-07 2016-04-27 Новартис Аг Иммунологически полезные соли аргинина
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
KR101716557B1 (ko) 2012-03-09 2017-03-14 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2875391A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
BR112019014397A2 (pt) 2017-01-31 2020-02-11 Pfizer Inc. Composições de neisseria meningitidis e métodos das mesmas
US20200325020A1 (en) * 2017-10-25 2020-10-15 Merck Sharp & Dohme Corp. Adjuvanted vaccines
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
AU4841693A (en) 1992-08-31 1994-03-29 North American Vaccine, Inc. Vaccines against group c neisseria meningitidis
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
WO1998053851A1 (en) 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO1999010497A1 (en) 1997-08-21 1999-03-04 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
ATE476508T1 (de) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic Neisseriale antigene
JP4399112B2 (ja) 1998-01-14 2010-01-13 カイロン ソチエタ ア レスポンサビリタ リミタータ ＮｅｉｓｓｅｒｉａＭｅｎｉｎｇｉｔｉｄｉｓ抗原
CN1227360C (zh) * 1998-02-05 2005-11-16 史密丝克莱恩比彻姆生物有限公司 Mage家族肿瘤相关抗原衍生物及其编码核酸序列
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
EP2261357A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
BR9910749A (pt) * 1998-05-29 2001-02-13 Chiron Corp Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
EP1741443B1 (en) * 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
JP2004511201A (ja) 1998-10-09 2004-04-15 カイロン　コーポレイション ナイセリアゲノム配列およびそれらの使用方法
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
JP3595264B2 (ja) 1998-11-03 2004-12-02 デ・スタート・デル・ネーデルランデン・ベルテゲンボールディクト・ドール・デ・ミニステル・バン・ベルジーン・ボルクスゲツォントヘイト・エン・クルトゥール 遺伝的に修飾されたグラム陰性細菌由来の低毒性ｌｐｓ
WO2000033882A1 (en) 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
TWI281403B (en) 1999-03-19 2007-05-21 Smithkline Beecham Biolog Vaccine
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
US8273360B2 (en) 2000-01-17 2012-09-25 Novartis Ag Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
ATE352631T1 (de) 2000-02-28 2007-02-15 Novartis Vaccines & Diagnostic Heterologe expression von neisseria proteine
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
BRPI0112928B1 (pt) 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
KR100947757B1 (ko) 2001-01-23 2010-03-18 아벤티스 파스퇴르 다가 수막구균 폴리사카라이드―단백질 접합체 백신
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP1777236B8 (en) 2002-03-26 2017-02-22 GlaxoSmithKline Biologicals SA Modified saccharides having improved stability in water for use as a medicament
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
DK2255826T3 (en) 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AU2003282498A1 (en) * 2002-10-07 2004-05-04 Chiron Corporation Hiv vaccine formulations
EP2353608B1 (en) 2002-10-11 2019-12-18 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US20070059329A1 (en) * 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
US20040235770A1 (en) * 2003-04-02 2004-11-25 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
PT1961426E (pt) * 2003-10-02 2011-06-28 Novartis Vaccines & Diagnostic Vacinas combinadas contra a meningite
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1706481A2 (en) * 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Vaccine
RU2347586C2 (ru) 2004-04-05 2009-02-27 Пфайзер Продактс Инк. Микрофлюидизированные эмульсии типа "масло в воде" и вакцинные композиции
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2434029T3 (es) * 2004-11-15 2013-12-13 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas que contiene antígeno de antrax, micropartículas de polímero biodegradable, y adyuvante inmunológico que contiene polinucleótido
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
KR101916787B1 (ko) * 2005-03-23 2019-01-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8156755B2 (en) * 2005-06-03 2012-04-17 Intervet International B.V. Refrigerator for storing vials and cartridge for use in the same
ATE536884T1 (de) 2005-06-27 2011-12-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
US20090010959A1 (en) 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
CA2643322C (en) * 2006-02-24 2015-07-21 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
AU2008259423A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines

Also Published As

Publication number Publication date
EP2200642B1 (en) 2012-04-18
ES2383231T3 (es) 2012-06-19
BRPI0818545A2 (pt) 2017-07-04
US20100285069A1 (en) 2010-11-11
JP2016029108A (ja) 2016-03-03
CN101951949B (zh) 2013-10-02
AU2008313424B2 (en) 2014-05-22
EP2200642A1 (en) 2010-06-30
RU2498815C2 (ru) 2013-11-20
PT2200642E (pt) 2012-05-30
BR122016015627A2 (pt) 2018-10-30
CA2925217A1 (en) 2009-04-23
JP5701058B2 (ja) 2015-04-15
CA2702871A1 (en) 2009-04-23
PL2200642T3 (pl) 2012-09-28
RU2013133864A (ru) 2015-01-27
WO2009050586A1 (en) 2009-04-23
ATE553774T1 (de) 2012-05-15
SI2200642T1 (sl) 2012-06-29
NZ584683A (en) 2012-05-25
MX340096B (es) 2016-06-27
EP2462949A3 (en) 2012-09-05
CN101951949A (zh) 2011-01-19
RU2010119947A (ru) 2011-11-27
AU2008313424A1 (en) 2009-04-23
DK2200642T3 (da) 2012-07-16
JP2013216704A (ja) 2013-10-24
US20160228529A1 (en) 2016-08-11
CY1112908T1 (el) 2016-04-13
EP2462949A2 (en) 2012-06-13
HRP20120433T1 (en) 2012-07-31
JP5925736B2 (ja) 2016-05-25
CO6270339A2 (es) 2011-04-20
JP2011500662A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
MX2010004271A (es) Formulaciones de vacuna meningococica.
MX348734B (es) Vacunacion multiple que incluye meningococcus del serogrupo c.
RU2349342C2 (ru) Менингококковые вакцины для введения через слизистую оболочку
CR10123A (es) Vacuna.
RU2378009C2 (ru) Иммунизация против менингококков серогруппы y с помощью белков
GB0500787D0 (en) Integration of meningococcal conjugate vaccination
CY1111814T1 (el) Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων
PL1755662T3 (pl) Połączone koniugaty meningokokowe ze wspólnym białkiem nośnikowym
WO2010067202A3 (en) Mixing lyophilised meningococcal vaccines with non-hib vaccines
WO2008063555A3 (en) Methods of enhancing immune response using electroporation-assisted vaccination and boosting
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
TH75448A (th) พอลิแซคคาไรด์ที่เป็นปลอกหุ้มของ Neisseria meningitidis ในการเป็นตัวกระตุ้นภูมิคุ้มกันทางเยื่อบุเมือก และสูตรผสมผลลัพธ์ที่ได้

Legal Events

Date Code Title Description
FG Grant or registration